Skip to main content

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Active, not recruiting · Phase 3 · NCT04988386

Conditions: Amyloid Cardiomyopathy, Transthyretin-Related

At a glance

Research payments reported, 2025
$337,921
U.S. investigators named
26
Sites paid
26
Planned or actual enrollment
389

About the trial

Sponsor
Eidos Therapeutics, a BridgeBio company
Tested
Acoramidis (AG10) (drug)
Dates
Started 2021-10-27; completion 2028-05-15
Results posted
Not yet

Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

From ClinicalTrials.gov, last updated 2025-10-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eidos Therapeutics, Inc. reported $337,921 in research payments for this study in 2025 (134 payments).

Products named: Attruby

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.